Qualigen therapeutics' novel direct pan-ras inhibitors presented at american association of cancer research (aacr) 2024 annual meeting

Poster includes preclinical data on novel direct pan-ras inhibitors carlsbad, calif., april 10, 2024 (globe newswire) -- qualigen therapeutics, inc. (“qualigen” or “the company,” nasdaq: qlgn) today announces a poster presentation on its preclinical novel direct pan-ras inhibitors was presented at the american association for cancer research (aacr) annual meeting 2024 held april 5 – 10 in san diego, california.
QLGN Ratings Summary
QLGN Quant Ranking